BioNews Texas has followed the trajectory of XBiotech’s Xilonix in a series of articles dating back to April 25th, reporting on the first patient enrolled in Phase II trials for company’s so-called first-in-class True Human antibody inflammation blocker for tumor growth and metastasis. According to the company’s recent press release, “sterile inflammation caused by malignant tumors is known to stimulate angiogenesis and tissue matrix remodeling, key steps in ongoing tumor growth and spread.” With this in mind, Xilonix has shown promise in earlier studies in fostering lean body tissue recovery and an improved overall survival rate. As a result, “US Oncology Research will join XBiotech’s pivotal Phase III study, which has been granted FDA Fast Track status. XBiotech plans to have 100 sites in the United States, with results intended to provide the basis for marketing approval.”
XBiotech’s collaboration with US Oncology Research will provide substantial leverage for the Phase III study by tapping into US Oncology Research’s national network of affiliated oncology centers. This network will be utilized in order to treat patients with Xilonix and report on the results of the treatment. As part of the treatment, “[p]atients enrolled in the trial will receive at least the current standard of care. With nearly 225 affiliated treatment research locations, US Oncology Research is one of the largest organizations in America focused on bringing physicians, clinics and patients together for innovative cancer care.”
XBiotech is particularly optimistic about its new relationship with US Oncology Research and how this strategic partnership can help to continue to fast-track the development of Xilonix: “US Oncology Research is a premier cancer research organization with a rich history of innovation and superb attention to patient needs, John Simard, CEO of XBiotech, commented, adding that, Its reach to cancer patients across the country is simply extraordinary. We are thus gratified to be working together with US Oncology Research to expand availability of this new and important drug to more cancer patients.”
Considering the solid, consistent results with previous Xilonix clinical studies, XBiotech remains confident that their new therapy for colorectal cancer will continue to reveal improved survival rates for colorectal cancer patients, as well as recovered body tissue.
Photo from http://aznow.biz